JOSÉ LUIS
CABRIADA NUÑO
Forscher bis um 2022
Ana
Gutiérrez Casbas
Publikationen, an denen er mitarbeitet Ana Gutiérrez Casbas (15)
2024
-
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612
-
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Pharmaceutics, Vol. 16, Núm. 5
2023
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
2022
-
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)
Journal of Clinical Medicine
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
2021
-
Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study
Journal of Clinical Medicine, Vol. 10, Núm. 13
2019
-
Granulocyte–monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis
Scandinavian Journal of Gastroenterology, Vol. 54, Núm. 4, pp. 459-464
2018
-
Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A Randomized multicentre clinical trial
Journal of Crohn's and Colitis, Vol. 12, Núm. 6, pp. 687-694
-
Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients’ point of view
Gastroenterologia y Hepatologia, Vol. 41, Núm. 7, pp. 423-431
-
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 8, pp. 839-851
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
2014
-
Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database
Journal of Crohn's and Colitis, Vol. 8, Núm. 7, pp. 654-661
2013
-
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome
Journal of Crohn's and Colitis, Vol. 7, Núm. 9, pp. 717-722
-
Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients
Inflammatory Bowel Diseases, Vol. 19, Núm. 7, pp. 1404-1410